FirsthandHealth
FDA Press AnnouncementsUnited States17 November 2026

FDA Approves Lembaz Injection for Rare Infantile-Onset Niemann-Pick Disease Type C

On November 17, 2026, the U.S. Food and Drug Administration approved Lembaz (adrabetadex) injection to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C. This rare genetic disorder affects about 1 in 150,000 people and stops the body from processing fats inside cells, causing progressive neurological damage. The approval applies to adults and children who weigh at least 7 kilograms (about 15 pounds) and developed neurological symptoms before age 6. A trained healthcare provider gives the drug as an injection into the spinal canal every two weeks. In clinical evaluations of 36 patients, Lembaz lowered the risk of death by 55 percent compared to an untreated control group. The median survival time rose from 4.9 years to 8.5 years. Lembaz carries a boxed warning because it can cause permanent hearing loss, requiring regular hearing tests throughout treatment. The FDA granted approval to Mandos, LLC.

What was announced

The U.S. Food and Drug Administration approved Lembaz (adrabetadex) injection on November 17, 2026. The approval allows the drug to be used to reduce the risk of death in adults and children with infantile-onset Niemann-Pick disease type C (NPC). To qualify for treatment, patients must weigh at least 7 kilograms (about 15 pounds) and have experienced neurological symptoms before age 6.

Patients receive Lembaz through an intrathecal injection, which means a healthcare provider injects the drug directly into the spinal canal every two weeks. The FDA reviewed data from 36 patients treated across three clinical studies and an expanded access program. Results showed a 55 percent reduction in the risk of death compared to a matched control group. Treated patients lived a median of 8.5 years, compared to 4.9 years for the control group.

What it means

Niemann-Pick disease type C is a rare inherited condition affecting roughly 1 in 150,000 people. It prevents cells from processing cholesterol and other fats. As these fats build up in the brain, patients lose movement, coordination, and the ability to swallow.

Before this decision, two treatments were approved for NPC, but neither demonstrated an ability to lower mortality rates. Those earlier therapies also included age and weight restrictions that limited their use in very young patients. Lembaz is the first approved option shown to help patients with infantile-onset NPC live longer.

The drug comes with serious safety risks. The FDA required a boxed warning for hearing impairment, including permanent hearing loss. Doctors must evaluate a patient's hearing before starting treatment and check it regularly afterward to adjust doses if necessary. Common side effects include balance problems, fatigue, vomiting, headache, fever, back pain, nausea, diarrhea, and cough.

What the announcement does not tell us

The FDA press release does not state how much Lembaz will cost or when it will become available to patients. It does not mention insurance coverage plans or patient assistance programs. Furthermore, the announcement does not specify how dose adjustments for hearing loss affect the drug's overall effectiveness.

How this was written

This analysis was written with AI from the official announcement below, using only facts that announcement states. The quoted wording is FDA Press Announcements’s own. Always check the original before acting on anything here.

FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.
Source: FDA Press Announcements

More from FDA Press Announcements

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.